Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Zenas BioPharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.72, Zenas BioPharma, Inc. trades at 172.2x sales and 8.7x book value. Over the last twelve months it generated about $11M of revenue and a net loss of $676M. It runs a gross margin of -656.6%, an operating margin of -4785.5% and a net margin of -4925.5%. It shows return on equity of -208.9%, return on invested capital of -86.0% and a free cash flow yield of -12.8%. On the balance sheet: a debt-to-equity ratio of 1.42 and a current ratio of 9.42. Over the past 52 weeks the share price ranged from $13.50 to $44.60, with a beta of -1.02.
Zenas BioPharma, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.